Geneva, Switzerland-based Alcon’s AcrySof IQ Vivity IOL, a presbyopia-mitigating lens, is now available to all U.S. ophthalmologists for use with patients who are undergoing cataract surgery, according to a news release.
AcrySof IQ Vivity uses Alcon’s proprietary non-diffractive X-Wave technology, which stretches and shifts light without splitting it to deliver monofocal-quality distance vision, strong intermediate vision and functional near vision.
The IOL received FDA approval in February 2020 and was made available to select U.S. ophthalmologists during a September 2020 pilot phase. The lens is already available in some European markets, along with Australia, New Zealand and Canada, with the company touting more than 125 million implants of the AcrySof IQ platform around the world so far.
In U.S. clinical trial data, patients who used the Vivity lens observed a 94% rate of “very good” or “good” vision at distance and 92% very good or good vision at arm’s length.
“With the introduction of Vivity, Alcon continues to demonstrate our ongoing commitment to growing our IOL portfolio and delivering differentiated innovations that meet surgeon and patient needs,” Alcon North America president Sergio Duplan said in the release. “We now offer two next-generation presbyopia-mitigating IOL options, with the PanOptix Trifocal for patients who want to be more spectacle independent at all distances and Vivity for patients who seek to improve their intermediate and near vision, with a monofocal-like visual disturbance profile.”